“Secret Sauce” algorithm in process of being added to the GenViro! meter, company’s initial manufacturing order will consist of 100,000 International GenViro! Covid-19 Saliva Swift Kits to fulfill orders and for inventory stocking
LOS ANGELES, CA / ACCESSWIRE / September 1, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) www.decisiondiagnostics.co, a leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters through its subsidiary Pharma Tech Solutions, Inc., today announced that we have set September 26, 2020 as the launch date for our International version GenViro! Covid-19 Saliva Swift Kit. The company has notified its Korean manufacturing partner that it will place an initial order for 100,000 kits on that day. As of that same day DECN will accept orders from International distributors. The first shipments are expected to be sent to India with an initial order for 50,000 kits. The company will wholesale the International GenViro! Swift Kits at an introductory price of $8.95. The suggested retail price has yet to be determined and might vary by country.
The Genviro! Covid-19 Saliva Swift Kits have undergone rigorous testing at the Company’s manufacturing and product development facility in Daegu Korea and will consist of International packaging with written instructions available in five languages: Spanish, French, German, Russian and English, a link to an instructional video soon to be available at the DECN web site, three (3) GenViro! Swift test strips, a saliva capture vessel and universal interface adapter. The meter to read and report the results (positive or negative) will be packaged separately. Meters will be pre-programmed to allow for 100 tests (uses).
“While we continue to seek our FDA authorization, we are immediately working with our Asian distributor to fulfill the first International order of at least 50,000 GenViro Swift Kits, and to secure additional orders as quickly as possible. With Covid-19 again rising dramatically in India, and with two failed attempts to address testing needs with kits previously ordered by Indian entities, the plan by our distributor to send the first international GenViro! Swift Kits to India could not come at a better time for that hard hit country,” said DECN CEO Keith Berman.”
“While we anticipate US FDA approval, we recognize that the rest of the world can use the benefits Genviro! provides,” said Berman. “Our international distributors will be responsible for capturing any certifications or approvals required to produce sales and we look forward to working with distributors around the globe to quickly bring this accurate, affordable, simple and scalable testing solution to market.”
ABOUT DECISION DIAGNOSTICS CORP
Decision Diagnostics Corp. is the leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters. DECN’s products are designed to operate efficiently and less expensively on certain glucose meters already in use by almost 7.5 million diabetics worldwide. With newly inspired technology diabetic test strips already in the final stages of development, DECN products compete on a worldwide scale with legacy manufacturers currently selling to 71+ percent of a $15+ billion at-home testing market. The company’s new GenViro!™ product designed to test for Covid-19, is not yet available in the United States or Puerto Rico, but Emergency (EUA) Waivers are in process with the U.S. FDA.
This release contains the company’s forward-looking statements which are based on management’s current expectations and assumptions as of August 31, 2020, regarding the company’s business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.
SOURCE: Decision Diagnostics Corp.
View source version on accesswire.com: